Rhea-AI Filing Summary
Arcutis Biotherapeutics, Inc. (ARQT) received a notice under Rule 144 that Terrie Curran intends to sell restricted common stock through Merrill Lynch. The notice covers 38,200 shares of common stock with an aggregate market value of $956,124.61, expected to be sold on or after August 27, 2026 on NASDAQ.
The shares relate to stock option exercises on May 31, 2023 for 11,148 shares and June 14, 2024 for 27,052 shares. In the preceding three months, Terrie Curran sold 1,072 shares of common stock for $27,912.35.
Positive
- None.
Negative
- None.
Key Figures
Shares to be sold under Rule 144: 38,200 shares Aggregate market value of shares to be sold: $956,124.61 Proposed sale date: August 27, 2026 +4 more
Shares to be sold under Rule 144 38,200 shares Common stock proposed for sale through Merrill Lynch
Aggregate market value of shares to be sold $956,124.61 Value of 38,200 common shares covered by the notice
Proposed sale date August 27, 2026 Expected sale date for covered common stock on NASDAQ
Stock option exercise shares (2023) 11,148 shares Common stock from stock option exercise on May 31, 2023
Stock option exercise shares (2024) 27,052 shares Common stock from stock option exercise on June 14, 2024
Shares sold in past 3 months 1,072 shares Common stock sold on August 20, 2026
Proceeds from recent sale $27,912.35 Value received for 1,072 shares sold on August 20, 2026
Key Terms
Rule 144, Stock Option Exercise, Form 144
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Stock Option Exercise financial
"Common | 05/31/2023 | Stock Option Exercise | Arcutis Biotherapeutics"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Form 144 regulatory
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
FAQ
What does the Form 144 filing disclose for Arcutis Biotherapeutics (ARQT)?
It discloses that Terrie Curran has filed a notice of proposed sale under Rule 144 for up to 38,200 shares of Arcutis Biotherapeutics common stock, with an aggregate market value of $956,124.61, expected to be sold on or after August 27, 2026 on NASDAQ.
What prior transactions by Terrie Curran in ARQT stock are disclosed?
The filing notes a sale on August 20, 2026 of 1,072 shares of Arcutis Biotherapeutics common stock for $27,912.35, and that the shares to be sold derive from stock option exercises on May 31, 2023 and June 14, 2024.
AI-generated analysis. How Rhea-AI works. Not financial advice.